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The Anticoagulant Mechanism of Action of Heparin in Plasma
H. C. Hemker, J.  Pieters, S. 869uin, and I  Lindhout
The process of blood coagulation has been de-
scribed as a series of enzyme activations and in
each step of this sequence, the activated zymogen
converts another zymogen to an active protease.
At present, we know that this series of linked pro-
teolytic reactions in fact comprise a series of inter-
linked positive and negative feedback loops. The
generation of activated clotting factors at a signifi-
cant rate requires the formation of a complex be-
tween a zymogerr, a cofactor and an enzyme on a
surface (phospholipid membranes). The positive
feedback loops funktion in the generation of
cofactors and procoagulant surfaces (activated
blood platelets) by products generated at later sta-
ges of the coagulation sequence. The negative
feedback loops cause the inactivation of the multi
molecular complex by destruction of the cofactor.
Most of our knowledge about the biochemis-
try of these reactions emerged from in vitrostudies
in purified systems. At present, little information is
available to what extent each of these reactions
contribute in the overall reaction rate of the blood
coagulation sequence.
Because heparin and heparin fractions, by
virtue of their anti-factor Xa and anti-thrombin
activity, might act on each of the zymogen-serine
protease and procofactor-cofactor transitions, it is
extremely difficult to assess the relative importan-
ce of the anti-factor Xa and anti-thrombin activity
to the overall rate of thrombin generation in plas-
ma. As a result, standardization of heparin and the
laboratory control of the clinical use of this anti-
thrombotic drug are highly debatable issues and
presently remain unresolved.
The aim of our current studies is to examine
separately in clotting plasma the contributions of
the heparin-dependent factor XA inhibition and
thrombin inhibition in the generation of thrombin.
To this end, we monitored the generation of acti-
vated clotting factors in plasma activated via the
intrinsic or extrinsic pathway in the presence of
heparin and heparin fragments. Because the cur-
rently used amidolytic assays for activated clotting
factors are insufficient to measure each of the ser-
ine proteases or cofactors separately in plasma, we
developed highly sensitive and specific bioassays.
Because of the large numbers of assays and their
handling complexityitwas highly desirable to have
a laboratory workstation to do the job. At present,
the following activated blood coagulation factors
can be measured utilizing the BIOMEK 1000
automated workstation: factor VIIIa, factor Va,
factor IXa and factor Xa. All these factors can be
accurately measured in the picomolar range.
The generation of factor Va, factor Xa, pro-
thrombinase and thrombin in thromboplastin-acti-
vated plasma has been analyzed in the absence and
presence of heparin and heparin fragments (low
molecular weight heparins). Our findings together
with those obtained with the synthetic pentasac-
charide heparin and standard heparin strongly
suggest hat the anti-factor Xa activity of heparin
contributed little in its anticoagulant activity. The
inhibition of factor Va generation, dependent on
the heparin anti-thrombin activity only, is of prime
importance to the inhibition of thrombin genera-
tion in plasma. The inhibition of thrombin genera-
tion by low molecular weight heparins was compa-
rable with that of standard heparin on the basis of
their respective anti-thrombin specific activities,
but not on basis of their anti-factor Xa activities.
In platelet rich plasma,low molecularweight
heparin has a relatively high anti-thrombin specific
activity when compared with standard heparin in a
range up to 0.2 USP units/ml. In contrast to stan-
dard heparin, low molecular weight heparin is
much less susceptible for neutralizationby platelet
factor 4.
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